Assessment of Glofitamab With Gemcitabine in DL...

By João L. Carapinha

August 19, 2025

A recent G-BA decision provides a systematic evaluation of Glofitamab Gemcitabine DLBCL, combined with Gemcitabine and Oxaliplatin (GemOx), for treating adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible fo...
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Eli Lilly’s Innovation Statement: Advocating Drug Pricing Reforms
Rare Medications Coverage in the Netherlands: Price Reductions Required
Strengthening the U.S. Pharmaceutical Supply Chain: Establishing a Strategic ...
Most Expensive Drugs 2025: Trends and Implications in US Pharma Pricing
Urgent Care Effectiveness: Exploring Canadian Centre Models and Health System...
France’s HAS Denies Ribociclib Breast Cancer Therapy for Early HR+/HER2...
Enhancing Benefit Assessments: Insights from IQWiG Real-World Data Report
NICE’s 2025 Guidance on Obesity Management Support
NICE HealthTech Methods Update
Navigating Challenges for Small Countries to Access Innovative Medicines
Dutch Pharmacoeconomic Redesign: Streamlined Structure and Enhanced Transpare...